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At the end of September, the Argentine Chamber of Deputies approved amendments to the
new intellectual property rights law that was passed last March. The amendments are aimed at
reducing criticism by the US and other countries, which say that, in its original form, the new
patent legislation did not provide adequate property protection for pharmaceutical companies.
Notwithstanding the amendments, foreign governments still say that many of the clauses included
in the law violate international agreements on patent rights contained in the General Agreement on
Tariffs and Trade (GATT).
Last March, the Argentine Congress passed a patent rights law that fundamentally altered the
country's outdated intellectual property rights legislation by extending patent protection to
pharmaceuticals. Drug products had not been included in the previous Argentine patent law, in
effect since 1864. Nevertheless, the new legislation granted domestic drug companies an eightyear grace period before foreign companies could be eligible to receive patent protection, meaning
that domestic companies could continue to sell pirated drugs in Argentina until the year 2003. US
and other foreign companies strongly objected to that clause and other stipulations in the new law,
which they said constituted unfair trade practices in violation of GATT (see NotiSur, 04/27/95).
The foreign pressures to rewrite the law generated a huge row between President Carlos Menem's
administration and the Congress, since the former generally supports the objections of the
multinational drug companies, while the latter which has been heavily lobbied by the domestic
drug industry claims it is protecting national interests against foreign intervention in Argentina's
internal affairs (see NotiSur, 06/08/95). In June, the Menem administration opened negotiations with
deputies from the governing Partido Justicialista (PJ) in the Senate and the Chamber of Deputies to
draw up compromise clauses in the patent legislation. As a result, the executive and the PJ deputies
agreed on a series of technical changes in the law that address many of the concerns of foreign
multinationals. Of the compromise clauses known as "corrective" legislation the most important is
an agreement to reduce from eight to five years the grace period in which domestic companies can
continue to sell imitation products before foreign companies will be eligible for patent protection.
The Argentine Congress claims that the time reduction constitutes a major concession to the foreign
companies since GATT agreements provide a 10-year grace period to developing nations before
they must bring their patent legislation in line with GATT rules and regulations. In addition, by
agreeing to corrective legislation, representatives of the PJ which controls a majority of seats in
both legislative chambers in effect reneged on the accord they negotiated with opposition parties
in Congress last March when the original patent law was approved. Indeed, when the Senate voted
on the corrective legislation in late July, it was approved solely by the votes of PJ senators with all
opposition parties opposing the changes. And, when the Chamber approved the corrective clauses
on Sept. 28 which paved the way for the new legislation to take effect on Oct. 1 all 58 opposition
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representatives also voted against. "With this vote the governing party has simply turned its back
on the consensus we tediously constructed last March, when the Chamber and the Senate voted
unanimously to pass the patent law," Alejandro Armendariz, a Chamber representative for the
Union Civica Radical (UCR), said after the Sept. 28 vote. "The governing party's willingness to cave
in to US pressures clearly demonstrates that it has completely renounced the historical respect for
nationalism embodied in the Peronist party."
Nevertheless, even if the corrective clauses do constitute important concessions to foreign
governments and multinational pharmaceutical companies, the changes are unlikely to satisfy
foreign critics, since many controversial clauses approved in the original patent law were left
unchanged. In particular, foreign drug companies bitterly object to the government's decision
to allow the newly formed Industrial Property Office which will oversee all disputes regarding
intellectual property rights to grant "compulsory licenses" to domestic companies to continue to sell
imitation products under certain conditions even when a foreign company has been granted patent
protection. In most cases, such special licenses would be granted if the domestic company could
show that the foreign manufacturer was charging above-average prices for its products and that the
domestic company could sell the product at a substantially cheaper rate.
Moreover, the foreign companies also object to what they consider "arbitrary" methods that the
Industrial Property Office will use for calculating royalty payments to the patent holders when
special licenses are granted to domestic companies. As a result, foreign governments especially the
US are expected to challenge the new patent rights law in the World Trade Organization (WTO),
despite the corrective legislation approved by the Menem government. In fact, another corrective
clause approved by the PJ stipulates that if the WTO were to rule against the special "compulsory
licenses," the Argentine government would be forced to respect the ruling and rescind the licenses.
That, in effect, provides a major incentive to the foreign multinationals, virtually inviting them to
push their respective governments to take their case to the WTO. [Sources: Journal of Commerce,
07/12/95; US Embassy- International Market Insights (Buenos Aires), 07/27/95, 08/24/95; Agence
France-Presse, 06/06/95, 06/07/95, 06/12/95, 06/17/95, 06/21/95, 07/19/95, 09/27/95, 09/28/95]

-- End --

©2011 The University of New Mexico,
Latin American & Iberian Institute
All rights reserved.

Page 2 of 2

